| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC2394 |
| Trial ID | NCT04450069 |
| Disease | Follicular Lymphoma | Relapsed/Refractory Diffuse Large B-Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Lymphoplasmacytic Lymphoma | Burkitt Lymphoma | Waldenstrom Macroglobulinemia | Diffuse Large B-Cell Lymphoma | Mantle Cell Lymphoma | Small Lymphocytic Lymphoma |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | CLBR001 |
| Co-treatment | SWI019 |
| Phase | Phase1 |
| Recruitment status | Active, Not Recruiting |
| Title | CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies |
| Year | 2020 |
| Country | United States |
| Company sponsor | Calibr, a division of Scripps Research |
| Other ID(s) | CBR-sCAR19-3001 |
| Cohort 1 | |||||||||
|
|||||||||